Camsing Healthcare (BAC) H2 2026 earnings summary

Executive summary

• FY2026 focused on retail rationalisation, cost control and operational efficiency; the annual loss narrowed while revenue declined after outlet closures and a more selective sales strategy.

• The financial position remained strained, with net liabilities of S$6.188m and cash of S$41,000 at 31 January 2026; continuing operations depend on controlling-shareholder support.

Financial highlights

• Revenue was S$4.105m versus S$4.783m in FY2025; gross profit was S$2.260m versus S$2.739m.

• Loss before tax and net loss narrowed to S$928,000 from S$2.302m; basic and diluted loss per share improved to 1.03 cents from 3.56 cents.

• Other income was S$889,000 versus S$1.869m, including S$476,000 from lease termination and S$199,000 of I-Nitra payables written back; FY2025 included S$1.335m of loans and interest waived.

• Marketing and distribution expenses fell to S$1.994m from S$3.374m; G&A declined to S$1.680m from S$1.954m, while finance costs decreased to S$277,000 from S$322,000.

• Operating cash outflow improved to S$321,000 from S$1.392m; financing generated S$256,000, and investing used S$22,000.

Outlook and guidance

• Priorities include strengthening Nature's Farm, growing digital customer engagement, improving inventory management and introducing products aligned with health and wellness demand.

• Management intends to improve operating performance and cash flow, pursue sustainable growth and maintain prudent financial discipline amid macroeconomic uncertainty and changing consumer spending.